Journal
HAEMATOLOGICA
Volume 92, Issue 3, Pages 414-417Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.10570
Keywords
donor lymphocyte infusion; relapse; haploidentical; transplantation
Categories
Funding
- Scientific Research fund for Capital Medicine Development [2005-1010]
- HI-tech research development program of China [2006AA02Z4A0, 2006AA02A405]
Ask authors/readers for more resources
In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after haploidentical hematopoietic stem cell transplantation (HSCT). Twenty patients received DLI at a median of 177 days after HSCT. Eight patients survived in complete remission for a median of 1118 days. The 2-year probability of leukemia-free survival was 40%. Acute graft-versus-host disease (GVHD) grade 3-4 occurred in six patients after DLI. GVHD prophylaxis reduced the incidence of acute GVHD. Our primary data showed that G-CSF-primed DLI with GVHD prophylaxis was a potentially effective therapeutic option for patients who relapsed after haploidentical HSCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available